samedan logo
 
 
spacer
home > epc > spring 2002 > what you should expect from a user-friendly edc solution
PUBLICATIONS
European Pharmaceutical Contractor

What You Should Expect from a User-Friendly EDC Solution

'User-friendly' is one of the most commonly misunderstood phrases in the computer lexicon. For years, every software package claimed to be 'user-friendly', diluting what the term actually means. Many purchasing agents began to ignore the claim because it was so difficult to quantify. Consequently, the term all but disappeared.

However, in the world of clinical trial software, it is dangerous to ignore the term 'user-friendly' in evaluations - particularly when investigator sites place such high importance on the concept. Being 'user-friendly' is an important criteria for software selection, but the trick is defining user-friendliness in a way that meets the needs of sites.

A critical point about the EDC selection process is that, generally, the decision-makers are the sponsor companies, and often the data management team for these companies plays an important role in the choice of EDC vendor. Although it is important that EDC software meet the data management requirements, it is absolutely critical that the initial users of the software (the personnel at the investigator site and the data monitors), readily accept the software. Without the site and monitor 'buy-in', data won't be entered into the site in a timely fashion and the software won't be used effectively. Without clean data available to data management, the usefulness of EDC is minimised.


Read full article >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Thomas Haskell, Director of Product Management at CB Technologies, Inc

Tom Haskell is Director of Product Management at CB Technologies, Inc. In this position, he is responsible for the strategic direction of the company's suite of clinical trial software products. A graduate of Harvard University, he has over 20 years of experience in software product strategy and full software life cycle development in many different industries.

Tom began his tenure at CB as a Strategic Consultant for many of the top pharmaceutical companies, including Pfizer and Aventis. Prior to joining CB, he served as Vice President and General Manager for MapQuest.com, a supplier of travel information on the Internet.

spacer
Thomas Haskell
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

4th Annual Patient Recruitment and Retention in Clinical Trials

13-15 October 2008, Amsterdam

Patient recruitment is now consuming thirty percent of clinical trial time - more time than any other clinical trial activity - and almost half of all trial delays result from patient recruitment problems. As the recruiting culture becomes more sophisticated and the forces affecting patient enrollment grow more numerous and complex, pharmaceutical companies are striving to discover new strategies to facilitate enrollment in clinical trials. With increasing industry pressure to develop, test and market greater numbers of new drugs faster, pharmaceutical companies need to perform clinical trials as quickly as possible. Inefficient patient recruitment processes is a formidable barrier to pharmaceutical companies' success in launching new products. Improving the patient recruitment process is imperative to avoid wasted investments and eliminate costly delays in bringing new drugs to market -- today and even more so in the not-so-distant future. Improved patient recruitment presents one of the largest opportunities for pharmaceutical companies to eliminate delays in clinical trials, thereby making it possible to reduce time to market.  With patent time limits and large overheads meaning that any delays in the development timeline can be disastrous, a good understanding of how to successfully recruit patients for trials is vital for any company looking to succeed.
More info >>

 
News and Press Releases

Azopharma Product Development Group, Inc

HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today the addition of innovative state-of-the-art equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, Florida. The most recent acquisition is the MG Futura Capsule Filler which delivers the latest in capsule filling technology. The company has also added a Bausch & Strobel Aseptic Filling Isolator, equipment that is ground-breaking in the powder filling process. These additions support our previously implemented XcelodoseTM powder micro-dosing system. With these technologies, Azopharma is able to provide its clients with all forms of the capsule filling process. The new equipment is part of Azopharma’s recent manufacturing expansion which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products...
More info >>

 

©2000-2007 Samedan Ltd.
About Us | Register | Login | Site Map | Terms and Conditions | Contact Us |
Add to favourites

Print this page

Send to a friend
Privacy statement